Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Therapy | 21 | 2025 | 744 | 5.250 |
Why?
|
| Dependovirus | 23 | 2025 | 659 | 4.700 |
Why?
|
| Genetic Vectors | 21 | 2025 | 820 | 3.200 |
Why?
|
| Gene Transfer Techniques | 8 | 2025 | 307 | 1.880 |
Why?
|
| Codon, Nonsense | 6 | 2024 | 51 | 1.710 |
Why?
|
| Mucopolysaccharidosis I | 4 | 2022 | 7 | 1.560 |
Why?
|
| Gene Editing | 8 | 2024 | 301 | 1.360 |
Why?
|
| Iduronidase | 3 | 2022 | 5 | 1.250 |
Why?
|
| Disease Models, Animal | 11 | 2025 | 2087 | 1.180 |
Why?
|
| CRISPR-Cas Systems | 6 | 2024 | 332 | 1.160 |
Why?
|
| RNA, Transfer | 2 | 2024 | 77 | 1.060 |
Why?
|
| 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 2025 | 9 | 0.970 |
Why?
|
| Maple Syrup Urine Disease | 1 | 2025 | 18 | 0.950 |
Why?
|
| Animals | 37 | 2025 | 19768 | 0.950 |
Why?
|
| Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase | 1 | 2024 | 4 | 0.950 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2024 | 7 | 0.950 |
Why?
|
| Mice, Inbred C57BL | 9 | 2024 | 3218 | 0.850 |
Why?
|
| Mice | 27 | 2025 | 10343 | 0.840 |
Why?
|
| Nervous System Diseases | 1 | 2024 | 105 | 0.820 |
Why?
|
| Homeostasis | 1 | 2025 | 343 | 0.800 |
Why?
|
| Anti-Mullerian Hormone | 5 | 2023 | 62 | 0.790 |
Why?
|
| Transduction, Genetic | 6 | 2025 | 233 | 0.780 |
Why?
|
| Phenotype | 3 | 2024 | 1158 | 0.770 |
Why?
|
| Spinal Cord | 3 | 2018 | 197 | 0.720 |
Why?
|
| Mice, Knockout | 2 | 2024 | 1999 | 0.680 |
Why?
|
| Genes, Recessive | 1 | 2018 | 52 | 0.610 |
Why?
|
| Infusions, Spinal | 1 | 2018 | 3 | 0.600 |
Why?
|
| Heterozygote | 1 | 2018 | 166 | 0.590 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 81 | 0.570 |
Why?
|
| Alleles | 1 | 2018 | 424 | 0.550 |
Why?
|
| Aminoglycosides | 2 | 2012 | 9 | 0.490 |
Why?
|
| Muscles | 3 | 2019 | 171 | 0.480 |
Why?
|
| Mutation | 4 | 2023 | 2471 | 0.470 |
Why?
|
| Glycosaminoglycans | 2 | 2011 | 18 | 0.470 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2015 | 70 | 0.460 |
Why?
|
| Adenoviridae | 3 | 2022 | 120 | 0.430 |
Why?
|
| Humans | 27 | 2025 | 60132 | 0.430 |
Why?
|
| Genetic Diseases, Inborn | 3 | 2022 | 37 | 0.410 |
Why?
|
| Designer Drugs | 1 | 2011 | 2 | 0.390 |
Why?
|
| Trisaccharides | 1 | 2011 | 9 | 0.390 |
Why?
|
| Epilepsy | 2 | 2023 | 111 | 0.360 |
Why?
|
| Transgenes | 4 | 2025 | 176 | 0.340 |
Why?
|
| Fibroblasts | 4 | 2023 | 370 | 0.340 |
Why?
|
| Nonsense Mediated mRNA Decay | 3 | 2022 | 21 | 0.330 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2023 | 477 | 0.250 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 2 | 2018 | 92 | 0.250 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2021 | 28 | 0.240 |
Why?
|
| Receptors, Peptide | 3 | 2021 | 31 | 0.240 |
Why?
|
| Liver | 2 | 2025 | 789 | 0.240 |
Why?
|
| Sialyltransferases | 2 | 2023 | 26 | 0.230 |
Why?
|
| Viral Tropism | 1 | 2025 | 55 | 0.230 |
Why?
|
| Cattle | 1 | 2025 | 306 | 0.230 |
Why?
|
| Recombinational DNA Repair | 2 | 2021 | 20 | 0.230 |
Why?
|
| Serogroup | 3 | 2025 | 32 | 0.230 |
Why?
|
| History, 21st Century | 1 | 2025 | 166 | 0.230 |
Why?
|
| History, 20th Century | 1 | 2025 | 230 | 0.220 |
Why?
|
| Recombination, Genetic | 2 | 2015 | 237 | 0.220 |
Why?
|
| Peptide Hormones | 1 | 2023 | 6 | 0.220 |
Why?
|
| Macaca mulatta | 1 | 2024 | 248 | 0.210 |
Why?
|
| Survival of Motor Neuron 2 Protein | 1 | 2023 | 6 | 0.210 |
Why?
|
| Survival of Motor Neuron 1 Protein | 1 | 2023 | 7 | 0.210 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2023 | 21 | 0.210 |
Why?
|
| Oxadiazoles | 1 | 2022 | 7 | 0.200 |
Why?
|
| Luciferases | 1 | 2022 | 109 | 0.200 |
Why?
|
| Codon, Terminator | 1 | 2022 | 21 | 0.200 |
Why?
|
| Lung | 2 | 2024 | 842 | 0.200 |
Why?
|
| Mucopolysaccharidosis II | 1 | 2021 | 11 | 0.190 |
Why?
|
| Tyrosinemias | 1 | 2021 | 19 | 0.190 |
Why?
|
| Frontotemporal Dementia | 1 | 2023 | 126 | 0.190 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2021 | 9 | 0.180 |
Why?
|
| Hereditary Sensory and Autonomic Neuropathies | 1 | 2021 | 11 | 0.180 |
Why?
|
| Ovarian Follicle | 2 | 2021 | 39 | 0.180 |
Why?
|
| Precision Medicine | 1 | 2022 | 105 | 0.180 |
Why?
|
| Ovary | 1 | 2021 | 96 | 0.180 |
Why?
|
| Mullerian Ducts | 1 | 2019 | 4 | 0.170 |
Why?
|
| Visual Cortex | 1 | 2019 | 27 | 0.160 |
Why?
|
| Uterus | 1 | 2019 | 41 | 0.160 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 41 | 0.160 |
Why?
|
| Bone Resorption | 1 | 2019 | 49 | 0.160 |
Why?
|
| Ovalbumin | 1 | 2019 | 113 | 0.160 |
Why?
|
| Adrenoleukodystrophy | 1 | 2018 | 8 | 0.160 |
Why?
|
| Genes, Reporter | 3 | 2018 | 243 | 0.160 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 697 | 0.160 |
Why?
|
| Endonucleases | 2 | 2018 | 81 | 0.150 |
Why?
|
| DNA End-Joining Repair | 2 | 2018 | 24 | 0.150 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2018 | 6 | 0.150 |
Why?
|
| Infusions, Intraventricular | 1 | 2018 | 8 | 0.150 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 176 | 0.150 |
Why?
|
| Osmotic Pressure | 1 | 2018 | 15 | 0.150 |
Why?
|
| Mice, Transgenic | 4 | 2018 | 1227 | 0.150 |
Why?
|
| Cerebrospinal Fluid | 1 | 2018 | 20 | 0.150 |
Why?
|
| Cerebrovascular Circulation | 1 | 2019 | 171 | 0.150 |
Why?
|
| Bone and Bones | 1 | 2019 | 156 | 0.150 |
Why?
|
| Osteoporosis | 1 | 2019 | 139 | 0.150 |
Why?
|
| Catheters, Indwelling | 1 | 2018 | 69 | 0.150 |
Why?
|
| Inverted Repeat Sequences | 1 | 2017 | 14 | 0.140 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2018 | 88 | 0.140 |
Why?
|
| Ovarian Reserve | 1 | 2017 | 8 | 0.140 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2018 | 63 | 0.140 |
Why?
|
| Biological Transport | 1 | 2018 | 288 | 0.140 |
Why?
|
| Contraceptive Agents | 1 | 2017 | 11 | 0.140 |
Why?
|
| Genetic Engineering | 1 | 2018 | 112 | 0.140 |
Why?
|
| Gene Silencing | 1 | 2019 | 379 | 0.130 |
Why?
|
| Embryonic Development | 1 | 2018 | 136 | 0.130 |
Why?
|
| Genome, Viral | 1 | 2017 | 122 | 0.130 |
Why?
|
| DNA, Viral | 1 | 2017 | 228 | 0.130 |
Why?
|
| Superoxide Dismutase | 1 | 2017 | 214 | 0.130 |
Why?
|
| Prostate | 1 | 2015 | 54 | 0.120 |
Why?
|
| Female | 10 | 2025 | 31250 | 0.120 |
Why?
|
| Targeted Gene Repair | 1 | 2014 | 3 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 183 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2022 | 770 | 0.120 |
Why?
|
| RNA Editing | 1 | 2014 | 21 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 138 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 443 | 0.110 |
Why?
|
| Base Sequence | 2 | 2019 | 1313 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 193 | 0.110 |
Why?
|
| Lumbar Vertebrae | 1 | 2015 | 144 | 0.110 |
Why?
|
| Bacterial Proteins | 2 | 2018 | 752 | 0.110 |
Why?
|
| RNA Splicing | 1 | 2014 | 160 | 0.110 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2014 | 133 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 1136 | 0.100 |
Why?
|
| Male | 8 | 2025 | 27971 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2019 | 620 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 330 | 0.100 |
Why?
|
| Peptide Chain Termination, Translational | 1 | 2012 | 16 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 712 | 0.100 |
Why?
|
| Biological Assay | 1 | 2011 | 54 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 647 | 0.090 |
Why?
|
| RNA Interference | 1 | 2014 | 592 | 0.090 |
Why?
|
| Embryo, Mammalian | 1 | 2011 | 161 | 0.090 |
Why?
|
| Lysosomes | 1 | 2011 | 163 | 0.090 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 182 | 0.080 |
Why?
|
| Femur | 1 | 2010 | 54 | 0.080 |
Why?
|
| Absorptiometry, Photon | 1 | 2010 | 89 | 0.080 |
Why?
|
| Contraception | 2 | 2023 | 67 | 0.080 |
Why?
|
| Brain | 1 | 2018 | 1493 | 0.080 |
Why?
|
| Microscopy, Electron | 1 | 2010 | 253 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 130 | 0.080 |
Why?
|
| Bone Density | 1 | 2010 | 174 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 525 | 0.080 |
Why?
|
| Spleen | 1 | 2010 | 486 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2010 | 558 | 0.080 |
Why?
|
| Injections, Spinal | 2 | 2018 | 43 | 0.080 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1983 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2013 | 1470 | 0.070 |
Why?
|
| Heart Failure | 1 | 2014 | 869 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 2 | 2018 | 354 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2025 | 286 | 0.060 |
Why?
|
| Neoplasms | 1 | 2014 | 1261 | 0.060 |
Why?
|
| Population Control | 1 | 2023 | 2 | 0.050 |
Why?
|
| Sterilization, Reproductive | 1 | 2023 | 7 | 0.050 |
Why?
|
| Animals, Wild | 1 | 2023 | 10 | 0.050 |
Why?
|
| Macaca fascicularis | 1 | 2023 | 47 | 0.050 |
Why?
|
| Gangliosides | 1 | 2023 | 20 | 0.050 |
Why?
|
| Cats | 1 | 2023 | 81 | 0.050 |
Why?
|
| Dipeptides | 1 | 2023 | 61 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 1384 | 0.050 |
Why?
|
| DNA Repeat Expansion | 1 | 2023 | 53 | 0.050 |
Why?
|
| C9orf72 Protein | 1 | 2023 | 98 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2022 | 38 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 95 | 0.050 |
Why?
|
| Motor Neurons | 1 | 2023 | 206 | 0.050 |
Why?
|
| Proteomics | 1 | 2023 | 264 | 0.050 |
Why?
|
| Inhibins | 1 | 2021 | 46 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 2021 | 230 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 93 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 157 | 0.040 |
Why?
|
| Neurovascular Coupling | 1 | 2019 | 1 | 0.040 |
Why?
|
| Cerebral Blood Volume | 1 | 2019 | 2 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 571 | 0.040 |
Why?
|
| Gray Matter | 1 | 2019 | 29 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2019 | 90 | 0.040 |
Why?
|
| Cartilage | 1 | 2019 | 36 | 0.040 |
Why?
|
| Fertility | 1 | 2019 | 85 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2019 | 112 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2019 | 203 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2019 | 176 | 0.040 |
Why?
|
| Capsid | 1 | 2019 | 89 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 169 | 0.040 |
Why?
|
| Brain Mapping | 1 | 2019 | 228 | 0.040 |
Why?
|
| Fallopian Tubes | 1 | 2018 | 12 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2019 | 205 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2019 | 236 | 0.040 |
Why?
|
| Astrocytes | 1 | 2018 | 116 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2019 | 298 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2017 | 7 | 0.040 |
Why?
|
| Ganglia, Spinal | 1 | 2017 | 23 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2017 | 36 | 0.040 |
Why?
|
| Oxygen | 1 | 2019 | 309 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2019 | 256 | 0.040 |
Why?
|
| Proteins | 1 | 2023 | 743 | 0.040 |
Why?
|
| Rats | 1 | 2021 | 1918 | 0.040 |
Why?
|
| Gene Order | 1 | 2017 | 29 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2018 | 258 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 883 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 86 | 0.040 |
Why?
|
| Blastocyst | 1 | 2018 | 76 | 0.040 |
Why?
|
| Granulosa Cells | 1 | 2017 | 15 | 0.030 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2017 | 6 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 848 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1565 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2017 | 114 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 110 | 0.030 |
Why?
|
| Reproduction | 1 | 2017 | 88 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 742 | 0.030 |
Why?
|
| Plasmids | 1 | 2017 | 283 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2017 | 231 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2019 | 508 | 0.030 |
Why?
|
| Serotyping | 1 | 2015 | 50 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 381 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1297 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 583 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 398 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2015 | 26 | 0.030 |
Why?
|
| Tropism | 1 | 2015 | 17 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2015 | 31 | 0.030 |
Why?
|
| Ascites | 1 | 2015 | 21 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 62 | 0.030 |
Why?
|
| Lidocaine | 1 | 2015 | 27 | 0.030 |
Why?
|
| Punctures | 1 | 2015 | 53 | 0.030 |
Why?
|
| Injections | 1 | 2015 | 79 | 0.030 |
Why?
|
| Cytokines | 1 | 2019 | 911 | 0.030 |
Why?
|
| DNA Replication | 1 | 2017 | 229 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 181 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 651 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2015 | 118 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 807 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 502 | 0.030 |
Why?
|
| Cell Line | 1 | 2017 | 2017 | 0.030 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2012 | 25 | 0.030 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2012 | 75 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 465 | 0.020 |
Why?
|
| Models, Biological | 1 | 2017 | 1143 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 855 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 943 | 0.020 |
Why?
|
| Adult | 2 | 2019 | 15985 | 0.020 |
Why?
|
| Middle Aged | 2 | 2019 | 16535 | 0.020 |
Why?
|
| Pregnancy | 1 | 2018 | 2367 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 2049 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 296 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 4396 | 0.020 |
Why?
|
| United States | 1 | 2022 | 7622 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2101 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 1110 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 5197 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 2891 | 0.020 |
Why?
|
| Aged | 1 | 2015 | 13581 | 0.010 |
Why?
|